Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ChemoCentryx, Inc.    CCXI

CHEMOCENTRYX, INC.

(CCXI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/22/2021 01/25/2021 01/26/2021 01/27/2021 01/28/2021 Date
64.4(c) 64.82(c) 59.29(c) 56.38(c) 56.76 Last
564 468 797 488 531 027 811 053 149 113 Volume
+1.77% +0.65% -8.53% -4.91% +0.67% Change
More quotes
Financials (USD)
Sales 2020 68,5 M - -
Net income 2020 -48,3 M - -
Net cash position 2020 387 M - -
P/E ratio 2020 -76,7x
Yield 2020 -
Sales 2021 51,4 M - -
Net income 2021 -99,7 M - -
Net cash position 2021 421 M - -
P/E ratio 2021 -39,2x
Yield 2021 -
Capitalization 3 902 M 3 902 M -
EV / Sales 2020 51,3x
EV / Sales 2021 67,8x
Nbr of Employees 82
Free-Float 76,4%
More Financials
Company
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168)... 
More about the company
Notations Surperformance© of ChemoCentryx, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CHEMOCENTRYX, INC.
01/07INSIDER TRENDS : Insider at ChemoCentryx Acquires Stock Via Option/Derivative Se..
MT
01/07INSIDER TRENDS : Insider at ChemoCentryx Acquires Stock Via Option/Derivative Se..
MT
01/06ChemoCentryx to Participate in Two Upcoming Investor Conferences
GL
2020CHEMOCENTRYX : Insider Sale at ChemoCentryx (CCXI) Deemed Significant
MT
2020INSIDER TRENDS : ChemoCentryx Insider Extends 90-Day Selling Trend
MT
2020SECTOR UPDATE : Health Care Stocks Flat to Higher on Premarket Tuesday
MT
2020ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacop..
AQ
2020ETF PREVIEW : ETFs, Futures Slump Lower as Concerns Over New Strain of COVID-19 ..
MT
2020ChemoCentryx Kidney Disease Drug Fails to Reach Primary Endpoint in Mid-Stage..
MT
2020CHEMOCENTRYX : Topline Results of ACCOLADE Trial of Avacopan for C3 Glomerulopat..
PU
2020CHEMOCENTRYX, INC. : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
2020ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacop..
GL
2020Biotechnology Sector's 2020 Cash Stockpile Growth Prepares More Firms to Mana..
MT
2020CHEMOCENTRYX : to Present at Two Upcoming Investor Conferences
AQ
2020ChemoCentryx to Present at Two Upcoming Investor Conferences
GL
More news
News in other languages on CHEMOCENTRYX, INC.
2020Aktien Schweiz Vorbörse: SMI nach Vortagesverlusten leicht erholt erwartet
2020La coentreprise Vifor-Fresenius présente des résultats de l'étude ACCOLADE
2020Vifor-Joint-Venture präsentiert erste Ergebnisse der ACCOLADE-Studie
2020Aktien Schweiz Vorbörse: Am US-Wahltag fester gesehen
2020Vifor Pharma macht mit Partnern weiteren Schritt mit Avacopan bei EU-Zulassun..
More news
Chart CHEMOCENTRYX, INC.
Duration : Period :
ChemoCentryx, Inc. Technical Analysis Chart | CCXI | US16383L1061 | MarketScreener
Technical analysis trends CHEMOCENTRYX, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 82,14 $
Last Close Price 56,38 $
Spread / Highest target 111%
Spread / Average Target 45,7%
Spread / Lowest Target 6,42%
EPS Revisions
Managers and Directors
NameTitle
Thomas J. Schall Chairman, President & Chief Executive Officer
Susan M. Kanaya EVP, Chief Financial & Administrative Officer
Catherine Lee Kelleher Senior Vice President-Clinical Development
Sangita Ghosh Senior Vice President-Technical Operations
Geoffrey M. Parker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CHEMOCENTRYX, INC.-8.95%3 902
CSL LIMITED-2.70%96 233
SAMSUNG BIOLOGICS CO.,LTD.-4.36%50 715
BIOGEN INC.8.29%40 802
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.12.91%40 785
ALEXION PHARMACEUTICALS, INC.3.53%34 072